All

Video: The 411 on 504's

BMX-411504-01.jpg

For caregivers of children with a chronic health condition, it is important to understand legal rights for academic accommodations.

Join BioMatrix as we host a webinar focused on facilitating academic success for children with special healthcare needs.

Overview: This program is designed to empower parents to understand their child’s rights for accommodations in the academic setting. The presentation provides information and resources to design and implement effective 504 plans, transition between grades, schools, and alternate academic settings during the time of COVID-19. Presented by a mother and educator with children who have multiple chronic health conditions, this presentation draws on research, resources, and personal experience.

Key Learning Objectives:

  • Understand qualifying conditions and rights for academic accommodations

  • Understand the components of a 504 plan

  • Learn how to effectively set-up, implement, utilize, and preserve a 504 plan

  • Understand 504 coverage in Pre-kindergarten, Primary, Secondary and Post-Secondary environments

  • Understand the impact of COVID-19 on 504's and other accommodations

  • Identify resources and support to help during the upcoming school year

Please direct any questions related to this webinar by email to: education@biomatrixsprx.com

Thank you!

About Kelly Lynn Gonzalez
Regional Care Coordinator / Education Development Specialist @ BioMatrix Specialty Pharmacy

Kelly Lynn Gonzalez is a patient, parent of patients, and spouse in the rare disease community. Having personal experience with bleeding disorders, autoimmune disease, PIDD, epilepsy, and cancer – Kelly presents material colored by nearly three decades of experience managing chronic health conditions.

Her presentation style draws on both personal journey and professional expertise to educate, inspire and empower audiences. She channels a sincere passion for helping others facing chronic illness with previous experience as a teacher to lead heartfelt and dynamic programming. Kelly holds an MBA and MA in Education.

Stay informed on the latest trends in healthcare and specialty pharmacy.

Sign up for our monthly e-newsletter, BioMatrix Abstract.

We value your privacy. Review our Privacy Policy here.

Read More

, ,

An Overview of Intravenous and Subcutaneous Immunoglobulin (IVIG/SCIG) In Immunology

, ,
iStock-1180608900.jpg

IVIG and SCIG are pinnacle therapies for the treatment of primary humoral immunodeficiencies and are gaining utility across the scope of immunology.

Immunoglobulin may be used to increase serum IgG, modulate the immune system, and help prevent recurrent infections.1 Depending on the specific indication, immunoglobulin therapy may be FDA approved or used off-label with recommendations from clinical guidelines.

Indications with FDA approval for IVIG2

Chart-1.jpg

Indications with off-label use for IVIG

Chart-2.jpg

Monitoring

Monitoring for IVIG patients typically includes:

  • Blood pressure before, during and after the infusion2
    • - IVIG may cause hypotension or hypertension
  • Renal function3
    • - Monitor before initiating therapy, and then at appropriate intervals.
    - IVIG has a US boxed warning for renal dysfunction.
  • IgG concentrations2,11,12
    • - Monitor before initiating therapy, and then every 4-6 months. Measure every 2-3 months if switching from IV to SC IG.
    - IgG reference level: 700-1600 mg/dL
    - Goal trough level: >600 mg/dL OR at least as high as the previous trough level from the previous IVIG dose.
  • IgA concentrations2,11
    • - Low levels of IgA may lead to the formation of IgA antibodies.
    - Patients with IgA antibodies are at a greater risk of infusion reactions from IVIG.
    - Use low IgA IVIG for patients with low IgA and monitor closely for infusion reactions.
    - IgA reference level: 70-400 mg/dL
  • Signs of thrombosis2
    • - IVIG has box warning for increased risk of thrombosis.
    - Patients who have difficulties ambulating may be at a greater risk of thrombosis events.
  • Clinical response

The role of subcutaneous immunoglobulin (SCIG)

SCIG offers several benefits for patients who receive immunoglobulin therapy. The primary benefit is convenience, as the patient may be trained to self-administer SCIG or be able to have a caregiver trained to administer at home. Patients who have a busy schedule, live far away from infusion centers or who have transportation barriers may find great freedom in switching from IVIG to SCIG. SCIG produces a less dramatic spike in serum IgG levels which is beneficial in reducing systemic side effects. Additionally, more frequent dosing of SCIG has been shown to produce higher trough levels and patients may experience less variations in clinical response.13

The main limitations of SCIG are increased infusion-site reactions, increased dosing frequency and less opportunity for healthcare monitoring during infusions. For these reasons, SCIG should be reserved for patients whose disease states are well controlled. If patients experience a decrease in therapeutic response while on SCIG, they may need to be switched back to IVIG therapy.

SCIG therapy is currently FDA approved for primary immunodeficiencies.2 Refer to each product’s prescribing information leaflet for dosing guidance.

Final considerations

The use of IVIG and SCIG in immunology is an evolving topic with new research conducted on a regular basis. Consult your institution’s clinical databases to stay up to date with the latest information regarding IVIG in specific indications.

BioMatrix is proud to make a difference in the communities we serve, one patient at a time.

Our clinicians and support staff offer a tailored approach to every therapeutic category, improving quality of life for patients and producing positive outcomes along the healthcare continuum. Learn more.

References

  1. Perez EE, Orange JS, Bonilla F, et al. Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol. 2017;139(3S):S1-S46. doi:10.1016/j.jaci.2016.09.023 

  2. Lexi-Drugs. [cited 2020 June 23] In Lexicomp Online [Internet]. Hudson, Ohio: Wolters Kluwer Clinical Drug Information, Inc. Available from:Available from: http://online.lexi.com.

  3. Boughton BJ, Jackson N, Lim S, Smith N. Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. Clin Lab Haematol. 1995;17(1):75-80.

  4. Chapel HM, Lee M, Hargreaves R, Pamphilon DH, Prentice AG. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma. Lancet. 1994;343(8905):1059-1063.

  5. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia (CGSIGCLL). N Engl J Med. 1988;319(14):902-907.

  6. Griffiths H, Brennan V, Lea J, Bunch C, Lee M, Chapel H. Crossover study of immunoglobulin replacement therapy in patients with low-grade B-cell tumors. Blood. 1989;73(2):366-368.

  7. Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. Transfus Med Rev. 2007;21(2)(suppl 1):s9-s56

  8. Feasby T, Banwell B, Benstead T, et al. Guidelines on the Use of Intravenous Immune Globulin for Neurologic Conditions. Transfus Med Rev. 2007;21(2)(suppl 1):57-107.

  9. Jahnke L1, Applebaum S, Sherman LA, et al. An evaluation of intravenous immunoglobulin in the treatment of human immunodeficiency virus-associated thrombocytopenia. Transfusion. 1994;34(9):759-764

Our entire team is committed to maintaining the health and wellbeing of those we are privileged to serve.

For updated information regarding our response to developments related to COVID-19, a letter from our CEO, and early refill requests, please click here.

Stay healthy, and be well.

We are with you and will get through this together.

Stay informed on the latest trends in healthcare and specialty pharmacy.

Sign up for our monthly e-newsletter, BioMatrix Abstract.

We value your privacy. Review our Privacy Policy here.

Read More

, ,

An Overview of Intravenous and Subcutaneous Immunoglobulin (IVIG/SCIG) In Neurology

, ,
iStock-1053434168.jpg

The utility of intravenous and subcutaneous immunoglobulin has evolved significantly from being a therapy narrowly used in primary immunodeficiencies, to becoming an option for patients in a wide array of clinical categories, including neurology.1

The exact role of IVIG in neurologic disorders varies based on the amount of clinical research for its use in each indication and can be categorized as being FDA approved (highest level of evidence), used off-label per guideline recommendations, or used with clinical caution in indications with more limited data.

Indications with FDA approval for IVIG

Chart-3.jpg

Indications with off-label use for IVIG

Chart-4.jpg

Indications with limited clinical support for IVIG

  • Stiff person syndrome12,13
  • Multiple sclerosis14,15,16
  • Childhood encephalitis17

IVIG is reserved as a last line treatment option in these indications if other treatments fail or cannot be tolerated by the patient. Dosing guidelines have yet to be clinically decided, and dosing is typically determined by the clinical judgement of the prescriber and individual, institutional protocols.

Monitoring

Monitoring for IVIG patients typically includes:

  • Blood pressure before, during and after the infusion3
    • - IVIG may cause hypotension or hypertension
  • Renal function3
    • - Monitor before initiating therapy, and then at appropriate intervals.
    - IVIG has a US boxed warning for renal dysfunction.
  • IgG concentrations3,18,19
    • - Monitor before initiating therapy, and then every 4-6 months. Measure every 2-3 months if switching from IV to SC IG.
    - IgG reference level: 700-1600 mg/dL
    - Goal trough level: >600 mg/dL OR at least as high as the previous trough level from the previous IVIG dose.
  • IgA concentrations3,18
    • - Low levels of IgA may lead to the formation of IgA antibodies.
    - Patients with IgA antibodies are at a greater risk of infusion reactions from IVIG.
    - Use low IgA IVIG for patients with low IgA and monitor closely for infusion reactions.
    - IgA reference level: 70-400 mg/dL
  • Signs of thrombosis3
    • - IVIG has box warning for increased risk of thrombosis.
    - Patients who have difficulties ambulating may be at a greater risk of thrombosis events.
  • Clinical response

The role of subcutaneous immunoglobulin (SCIG)

SCIG offers several benefits for patients who receive immunoglobulin therapy. The primary benefit is convenience, as the patient may be trained to self-administer SCIG or be able to have a caregiver trained to administer at home. Patients who have a busy schedule, live far away from infusion centers, or who have transportation barriers may find great freedom in switching from IVIG to SCIG. SCIG produces a less dramatic spike in serum IgG levels which is beneficial in reducing systemic side effects. Additionally, more frequent dosing of SCIG has been shown to produce higher trough levels, and patients may experience less variations in clinical response.20

The main limitations of SCIG are increased infusion-site reactions, increased dosing frequency, and less opportunity for healthcare monitoring during infusions. For these reasons, SCIG should be reserved for patients whose disease states are well controlled. If patients experience a decrease in therapeutic response while on SCIG, they may need to be switched back to IVIG therapy.

SCIG therapy, Hizentra, is currently FDA approved for CIDP.3 Refer to each product’s prescribing information leaflet for dosing guidance.

Final considerations

The use of IVIG and SCIG in immunology is an evolving topic with new research conducted on a regular basis. Consult your institution’s clinical databases to stay up to date with the latest information regarding IVIG in specific indications.

BioMatrix is proud to make a difference in the communities we serve, one patient at a time.

Our clinicians and support staff offer a tailored approach to every therapeutic category, improving quality of life for patients and producing positive outcomes along the healthcare continuum. Learn more.

References

  1. Hartung HP, Mouthon L, Ahmed R, Jordan S, Laupland KB, Jolles S. Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurology. Clin Exp Immunol. 2009 Dec;158 Suppl 1(Suppl 1):23-33. doi: 10.1111/j.1365-2249.2009.04024.x. PMID: 19883421; PMCID: PMC2801038.

  2. Hughes RA, Donofrio P, Bril V, et al., for the ICE Study Group. Intravenous immune globulin (10 percent caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomized, placebo-controlled trial. Lancet Neurol 2008 Feb;7(2):136–44.

  3. Lexi-Drugs. [cited 2020 June 23] In Lexicomp Online [Internet]. Hudson, Ohio: Wolters Kluwer Clinical Drug Information, Inc. Available from:Available from: http://online.lexi.com.

  4. Elovaara I, Apostolski S, van Doorn P, et al; EFNS. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS Task Force on the Use of Intravenous Immunoglobulin in Treatment of Neurological Diseases [published correction appears in Eur J Neurol. 2009;16(4):547]. Eur J Neurol. 2008;15(9):893-908.[PubMed 18796075]

  5. Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2012;78(13):1009-1015.[PubMed 22454268]

  6. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Lancet. 1997;349(9047):225-230.[PubMed 9014908]

  7. Raphael JC, Chevret S, Harboun M, Jars-Guincestre MC; French Guillain-Barré Syndrome Cooperative Group. Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry. 2001;71(2):235-238.[PubMed 11459901]

  8. Bain PG, Motomura M, Newsom-Davis J, et al. Effects of Intravenous Immunoglobulin on Muscle Weakness and Calcium-Channel Autoantibodies in the Lambert-Eaton Myasthenic Syndrome. Neurology. 1996;47(3):678-683.[PubMed 8797464]

  9. Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76(23):2017-2023.[PubMed 21562253]

  10. Gajdos P, Tranchant C, Clair B, et al; Myasthenia Gravis Clinical Study Group. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized double-blind clinical trial. Arch Neurol. 2005;62(11):1689-1693.[PubMed 16286541]

  11. Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. 2007;68(11):837-841.[PubMed 17353471]

  12. Dalakas MC, Fujii M, Li M, Lutfi B, Kyhos J, McElroy B. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med. 2001.

  13. Dalakas MC, Fujii M, Li M, McElroy B. The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome. Neurology. 2000. 

  14. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet. 1997.

  15. Achiron A, Kishner I, Dolev M, et al. Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol. 2004.

  16. Sorensen PS, Haas J, Sellebjerg F, Olsson T, Ravnborg M, Group TS. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology. 2004.

  17. Iro MA, Martin NG, Absoud M, Pollard AJ. Intravenous immunoglobulin for the treatment of childhood encephalitis. Cochrane Database Syst Rev. 2017;10(10):CD011367. Published 2017 Oct 2. doi:10.1002/14651858.CD011367.pub2

  18. Dati F, Schumann G, Thomas L, et al. Consensus of a group of professional societies and diagnostic companies on guidelines for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC/BCR/CAP Reference Material (CRM 470) Eur J Clin Chem Clin Biochem. 1996;34:517–20. International Federation of Clinical Chemistry, Community Bureau of Reference of the Commission of the European Communities, College of American Pathologists.

  19. Agarwal S, Cunningham-Rundles C. Assessment and clinical interpretation of reduced IgG values. Ann Allergy Asthma Immunol. 2007;99(3):281–283

  20. Shrestha P, Karmacharya P, Wang Z, Donato A, Joshi AY. Impact of IVIG vs. SCIG on IgG trough level and infection incidence in primary immunodeficiency diseases: A systematic review and meta-analysis of clinical studies. World Allergy Organ J. 2019 Oct 9;12(10):100068. doi: 10.1016/j.waojou.2019.100068. PMID: 31641401; PMCID: PMC6796775.

Our entire team is committed to maintaining the health and wellbeing of those we are privileged to serve.

For updated information regarding our response to developments related to COVID-19, a letter from our CEO, and early refill requests, please click here.

Stay healthy, and be well.

We are with you and will get through this together.

Stay informed on the latest trends in healthcare and specialty pharmacy.

Sign up for our monthly e-newsletter, BioMatrix Abstract.

We value your privacy. Review our Privacy Policy here.

Read More

, , ,

What to Expect from Intravenous Immunoglobulin (IVIG) Therapy

, , ,
iStock-1142997722.jpg

What is intravenous immunoglobulin (IVIG)?

IVIG is a blood product made from the donated antibodies of between 1,000-15,000 human donors per batch.1 Antibodies are proteins in your body that help fight infection. Your body has different antibodies to fight different infections, like how you have different keys for different locks. If your body does not have enough antibodies or has damaged antibodies, IVIG can help replace them.

Why would I need IVIG?

IVIG may be prescribed for different reasons. The most common reasons include:

  • Immunodeficiency disorders
    • - Primary immunodeficiencies (PID)
    - Common variable immunodeficiency (CVID)
  • Autoimmune disorders
    • - Immune thrombocytopenia (ITP)
    - Autoimmune hemolytic anemia (AIHA)
    - Guillain-Barre syndrome (GBS)
  • Neurologic disorders
    • - Chronic inflammatory demyelinating polyneuropathy (CIDP)
    - Multifocal motor neuropathy (MMN)
    - Myasthenia Gravis
    - Multiple sclerosis (MS)
    - Stiff person syndrome (SPS)
  • Organ transplant
    • - Desensitization
    - Post-transplant maintenance
    - BK virus

What can I expect before starting therapy?

Before starting IVIG therapy your doctor will perform the necessary tests to determine whether IVIG therapy would be a good fit for you. Once you and your doctor make the decision to start IVIG, you will then decide where you will receive your IVIG infusions. Options include a doctor’s office, infusion centers and even your own home.

Before your first infusion, your pharmacist will call you to review your medical history, infusion date and other information for the success of your infusion.

What can I expect the day of infusion?

The day of infusion, you will have a healthcare professional administer your IVIG. IVIG is given through a vein which may be accessed from your arm, a port or PICC line. Your doctor may prescribe pre-medications such as acetaminophen or diphenhydramine to prevent side effects such as headache and infusion reactions.

During your infusion, your nurse or doctor will likely monitor your blood pressure. It is also important to stay hydrated during the infusion, and you may be given IV fluids or be encouraged to drink fluids by mouth. In total your infusion will take between 2 to 4 hours. Remember to have a cell phone, book, or other activity that you can use to relax during the infusion.2

What are the side effects of IVIG?

Like any medication, IVIG is associated with certain side effects. Every patient will experience IVIG differently. You may have no side effects at all, or you may have several side effects. The most common side effects include:

  • Headache (mild-severe)
  • Flu-like symptoms
  • Injection site reactions
  • Feeling tired
  • Blood pressure changes

Seek medical attention immediately if you experience or think you might be experiencing any of the following rare but serious side effects:

  • Renal dysfunction
  • Allergic reaction (hives, swelling of the lips, tongue, or face)
  • Thrombosis, or clotting
  • Aseptic meningitis (severe headache, confusion, stiff neck, fever, fatigue)

Your doctor and pharmacist are there to help make IVIG as safe and comfortable as possible. If any side effect is troubling you, start a conversation. They may be able to slow the infusion rate to help reduce side effects or offer ways to help side effects such as over the counter pain relievers or cold/warm packs for infusion site reactions.3

How should I store IVIG?

IVIG should be stored in the refrigerator. The best place is in the middle of the fridge. Avoid the back of the fridge where it may be colder and the door, where it may be warmer. Do NOT heat, freeze, or shake your IVIG medication.3

Can I get immunizations while on IVIG?

Immunizations may not work as well while on IVIG. If possible, it is recommended to receive your vaccines prior to beginning your IVIG therapy. Talk to your doctor about the best vaccine schedule for you.2

More questions?

Contact your doctor or pharmacist! This article and others are not a replacement for the direct advice of your doctor or pharmacist. It is important for you to feel confident and comfortable with your infusion. Your health care team is there to help.

BioMatrix is proud to make a difference in the communities we serve, one patient at a time.

Our clinicians and support staff offer a tailored approach to every therapeutic category, improving quality of life for patients and producing positive outcomes along the healthcare continuum. Learn more.

References

  1. Jolles S, Sewell WA, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin Exp Immunol. 2005 Oct;142(1):1-11. doi: 10.1111/j.1365-2249.2005.02834.x. PMID: 16178850; PMCID: PMC1809480.

  2. Silvergleid A. Intravenous immune globulin ivig beyond-the-basics [Internet]. UpToDate. 2020 [cited 2020Jun23]. Available from: https://www.uptodate.com/contents/intravenous-immune-globulin-ivig-beyond-the-basics

  3. Lexi-Drugs. [cited 2020 June 23] In Lexicomp Online [Internet]. Hudson, Ohio: Wolters Kluwer Clinical Drug Information, Inc. Available from:Available from: http://online.lexi.com.

Stay informed on the latest trends in healthcare and specialty pharmacy.

Sign up for our monthly e-newsletter, BioMatrix Abstract.

We value your privacy. Review our Privacy Policy here.

Read More

BioMatrix Specialty Pharmacy Awarded Preferred Bleeding Disorder Provider Status by AscellaHealth

BioMatrix Specialty Pharmacy Awarded Preferred Bleeding Disorder Provider Status by AscellaHealth

Media Contact: Tara Marchese
Corporate Director of Marketing
Tel: 954-908-7636
Email: tara.marchese@biomatrixsprx.com

FOR IMMEDIATE RELEASE
[DOWNLOAD PDF]

Plantation, FL – July 13, 2020 – BioMatrix Specialty Pharmacy announced today preferred network status for AscellaHealth’s bleeding disorder patient population. The decision to include BioMatrix in the PBM’s national network was based on overall clinical expertise and extensive bleeding disorder experience, operational efficiencies, data reporting capabilities, and competitive pricing model. Beginning July 1, 2020, BioMatrix became one of just four specialty pharmacies selected by the PBM to hold preferred provider status.

AscellaHealth is a national Specialty PBM serving commercial, Medicare, and Medicaid plans. The rapidly growing organization includes over 1 million covered lives and has earned a name by providing high quality care for patients and substantial cost savings for plan sponsors. “We are excited to be working with BioMatrix to support our patients with bleeding disorders and look forward to continuing to provide innovative service models.” Stated Dea Belazi, President & CEO of AscellaHealth.

“BioMatrix and AscellaHealth share the same patient-centric approach and an ongoing commitment to meeting and exceeding the needs of patients and other healthcare stakeholders,” stated Nick Karalis CEO of BioMatrix. “We are very excited about our expanding partnership and look forward to providing outstanding service to AscellaHealth’s bleeding disorder patient population.”

About BioMatrix Specialty Pharmacy

BioMatrix Specialty Pharmacy offers comprehensive, nationwide specialty pharmacy services and digital health technology solutions for patients with chronic, difficult to treat conditions. Our commitment to every patient is to provide individualized pharmacy services, timely access to care, and focused education and support. We offer a tailored approach for a wide range of therapeutic categories, improving health and empowering patients to experience a higher quality of life.

About AscellaHealth

AscellaHealth, a national Specialty PBM serving commercial, Medicare and Medicaid segments offers high quality prescription drug management services along with other customizable services, such as carved-out specialty pharmacy services and cost-savings discount programs through its unique and proprietary service that extends discounts on prescription medications to customers more than any other in the industry.

Read More

There’s No Going Back - Virtual Patient Support is Here to Stay: NASP Podcast

Our Chief Operating Officer, Meagan Sampogna, PhD., RHIA, recently participated in a podcast with the National Association of Specialty Pharmacy discussing continuity for patients with chronic health conditions during the COVID-19 pandemic.

image.jpg

Participants:
Sheila Arquette, Executive Director, NASP
Melissa Kozak, RN, CRNI, CEO, Citus Health
Meagan Sampogna, COO, BioMatrix Specialty Pharmacy

Purpose: 

Discuss partnership and innovative solution to ensure business continuity for specialty patients during COVID-19 pandemic.

This episode is sponsored by the University of California Irvine, UCI, Master of Science in Pharmacology, learn more: https://sites.uci.edu/mspharmacology/ 

Read More

Video: It's OK To Not Be OK

WEBINAR-MC-01.png

This program empowers individuals to identify, address, and overcome challenges during difficult times.

It’s OK to Not Be OK provides tools for patients and caregivers to handle depression, anxiety and pain management.

The presentation follows the inspirational story of a mother who is no stranger to managing a rare, chronic health condition. Learn about her struggle with depression and how she was able to overcome significant adversity by accepting shortcomings and pushing forward through the toughest times.

Key Learning Objectives:

  • Learn signs and symptoms of “situational depression” and understand its prevalence in people with rare and chronic health conditions

  • Identify behavioral presentations of anxiety, frustration, and burnout

  • Understand how to build and engage support systems when you need help

  • Understand you are not alone

Please direct any questions related to this webinar by email to: education@biomatrixsprx.com

Thank you!

About Kelly Lynn Gonzalez
Regional Care Coordinator / Education Development Specialist @ BioMatrix Specialty Pharmacy

Kelly Lynn Gonzalez is a patient, parent of patients, and spouse in the rare disease community. Having personal experience with bleeding disorders, autoimmune disease, PIDD, epilepsy, and cancer – Kelly presents material colored by nearly three decades of experience managing chronic health conditions.

Her presentation style draws on both personal journey and professional expertise to educate, inspire and empower audiences. She channels a sincere passion for helping others facing chronic illness with previous experience as a teacher to lead heartfelt and dynamic programming. Kelly holds an MBA and MA in Education.

Stay informed on the latest trends in healthcare and specialty pharmacy.

Sign up for our monthly e-newsletter, BioMatrix Abstract.

We value your privacy. Review our Privacy Policy here.

Read More

,

Patient Perspective: Tracy

,

Learning, connecting, and sharing stories is an essential component of building community.

BMX-Patient-P-Tracey-01.jpg

For people living with a rare or chronic health condition, just knowing there are others out there who have walked in similar shoes can be a source of comfort and motivation.

In our first edition, we catch up with Tracy, who shares her story before and after kidney transplant.

Tracy, tell us why you needed to have a transplant?

Due to kidney disease caused by Type 1 diabetes, I found out I needed to have a transplant. When first hearing this from my doctor, to put it mildly, I was shocked. I had no idea what was happening to my body.

What was your life like before you had your transplant?

My sugar levels were not good - I was tired all the time. In January 2009, I underwent surgery and received a kidney and pancreas transplant. Unfortunately, my body quickly rejected the organs and caused me to become very ill. The organs were removed just 5 days later and required 16 blood transfusions. The surgeon reconnected my original organs, which remain in your body following a transplant. After that, I had to receive weekly iron infusions. Trudging along, my original organs held up until May 2010 when I needed to start dialysis.

For the next 3½ years, I received dialysis 3 times per week. My life became all about these 4-hour sessions. Prior to beginning dialysis, a fistula was inserted into my arm. A fistula is a surgically created vascular passageway to make dialysis easier. Pills were taken with each meal and snack, sodium was avoided at all costs, and fluid intake had to be carefully monitored and limited - for example, soup was drained and eaten with a fork and high-sodium restaurants were avoided. Due to the dialysis schedule, vacations were out of the question.

Even though it made me feel better, dialysis also wore me out and took a toll on my body. Everything dialysis entails – food, liquids, fistula, medications, schedules – was all I thought about. When I look back, I realize I was just living day by- day, with no real thought to the future.

Download our free Transplant Patient Medication Guide with helpful information about common medications used after transplant.

What role did IVIg have in your transplant?

My doctor explained, due to my existing organs and the previous blood transfusions, I now had 100% antibodies. Simply put, another transplant would be very difficult as my body would likely again reject the organ. My doctor proceeded to tell me about a study using IVIg. IVIg is supposed to lower antibodies, so another transplant could be possible; he wanted me to try it. Eager to do all I could to prepare for a successful transplant, I received IVIg for 7 months. A nurse came to my home every 2 weeks to administer the 4-hour infusion.

In January 2014, a kidney became available. IVIg helped ensure the transplant was a success! Without IVIg, I would still be on dialysis. Between the family that lovingly donated the kidney and the benefits of IVIg, I feel so fortunate to have been given a second chance to have a “normal” life and be free of the burden of dialysis!

What challenges have you faced post-transplant?

The biggest post-transplant challenge has been changing the way I eat and drink and getting used to the anti-rejection medications. After years of scrutinizing fluid intake, it was difficult to suddenly start drinking tons of water, which is needed to keep the new kidney functioning properly. I still think of fluid in ounces, but it has become easier with time.

The transplant medication routine was very confusing at first. It didn’t help that I felt a little out of it. Someone at the clinic suggested I was experiencing ‘transplant head.’ My husband had to oversee my meds for a little while, but I finally caught on. With time, the fuzzy feeling began to clear up and eventually went away.

Another challenge is that each medication comes with different side effects, which you learn to deal with. Some of the issues I’ve experienced include osteoporosis due to steroids, leading to some issues with my knee and foot. The medicines have caused some puffiness, weight gain, and stomach trouble, so I do watch my diet carefully. I’ve also experienced mild depression, which I understand is somewhat expected. Overall though, it hasn’t been too bad.

Our IVIg and SCIg medication guides make it easy to compare products and reach decisions to fit the needs of your patients. Download these free charts now.

What role has your specialty pharmacy played in helping manage your care?

For the 7 months of receiving IVIg infusions, BioMatrix Specialty Pharmacy shipped all the medication and supplies straight to my home. [When] the homecare nurse arrived, she would have everything needed already at my house. If we had any question at all, we just called BioMatrix. They were very familiar with my history and medical needs. It was comforting to know people so personable and knowledgeable were just a call away. 

What advice would you offer to others with the same diagnosis?

Reducing antibodies with IVIg gave me an opportunity I never thought I’d see again. I’m so happy IVIg is available, allowing me to have a successful outcome. For patients who struggle with high antibodies and who are facing a transplant, I totally recommend speaking to your doctor about it. When you get that crucial call that an organ is available, it feels great to know you have done everything possible to prepare for a successful transplant! I’ve had my kidney now for 5 years! Thank you to my kidney donor, my doctors, IVIg and BioMatrix! I am so very thankful for this second chance at life!

Stay informed on the latest trends in healthcare and specialty pharmacy.

Sign up for our monthly e-newsletter, BioMatrix Abstract.

We value your privacy. Review our Privacy Policy here.

Read More

Video: Health Insurance Basics. Everything You Didn't Know You Need To Know

BMX-HIB-HEADER-01.jpg

This program promotes understanding of health insurance basics.

It covers simple terminology like HMO, PPO, premiums, copays, and coinsurance; offers an overview of the major health plan types—private/employer, ACA, and government; discusses structures of employer-sponsored health plans that are fully vs. self-insured; examines the differences in health savings accounts like HSA’s and HRA’s; and cautions about recent accumulator adjustor policies related to manufacture copay coupons.

Attendees will come away with a firm understanding of the terms/jargon used by health plans in addition to greater comprehension of health plan types and their coverage differences.

Key Learning Objectives:

  • Participants will understand key insurance terminology like HMO, PPO, premiums, copays, coinsurance, etc.

  • Participants will learn the variances between private/employer, ACA, and government plans, as well as the difference between at-risk/self-insured policies vs. fully insured plans and their impact upon employers and plan members.

  • Participants will gain an understanding of formulary and the philosophy of PBMs and formulary management and how this drives current insurance policy making.

  • Participants will learn about recent insurance policy changes that have affected access to specialty medication: copay accumulator adjustors, step therapy, and pharmacy mandates for specialty medications. They will understand what these policies achieve, how they can disrupt or undermine access, and how patients can successfully navigate these issues.

  • Participants will be instructed in the insurance appeals process and will learn best practices for winning an appeal.

The information contained in this video is provided for informational and educational purposes only, and should not be construed as legal or clinical advice on any subject matter.

Please direct any questions related to this webinar by email to: Shelby.Smoak@biomatrixsprx.com

Thank you!

About Shelby Smoak
Advocate & Education Specialist at BioMatrix Specialty Pharmacy

8f1473e8-c63c-4af6-98da-8521ab41e8e6.jpg

Shelby Smoak is a tireless advocate for patients with chronic health conditions. In the 90s, his experience living with a bleeding disorder and HIV led him to become actively involved in advocacy. He’s been saturated in the ever-changing dynamics of healthcare ever since. Shelby helps others understand complicated health policy and serves as a voice for patients with rare conditions across the nation. He’s been featured on TV and radio, including NPR. Shelby served on the board for the Hemophilia Association of the Capitol Area and currently serves on the Pfizer B2B board. A former literature professor, Shelby is also a writer and a musician. Awarded a Pen/American grant for writers living with HIV, Smoak holds a Ph.D. in Literature and an M.A. in English. His book, “Bleeder: A Memoir” received praise from sources as diverse as The Minneapolis Star Tribune, Library Journal, and Glamour, and has won several awards, including “Best of the Best” by the American Library Association.

Stay informed on the latest trends in healthcare and specialty pharmacy.

Sign up for our monthly e-newsletter, BioMatrix Abstract.

We value your privacy. Review our Privacy Policy here.

Read More

, , , ,

Three Simple Ways Medical Providers Can Improve Therapy Adherence

, , , ,
ADHERENCE.jpg

Filled prescriptions that lay wasting in pill boxes and bottles do nothing for patients while costing payers $ billions each year. No one can ‘make’ people stick to their treatment plans. The answer to “are you taking your medications?” is usually “yes.” But the statistics tell us that “yes” often means “sometimes” or “no”. And while it’s common to embellish lifestyle choices to our healthcare provider (i.e. when 1-3 drinks per week really means 5-7), not adhering to a prescribed treatment plan is a big deal. And can be very dangerous.

Data shows that in 2018, over 3.7 billion retail and mail order prescription drugs were filled at pharmacies by payers costing them over $510 billion.(1) And only 30% to 50% of drugs were being taken as prescribed. In other words, roughly $250 billion worth of drugs had 0 impact and were thrown away. The scariest part is that roughly two-thirds of those (many times life-saving) prescription drugs were intended to treat chronic, many times deadly, disease. (2) 

Used to treat chronic, more complex conditions, specialty drugs are especially susceptible to non-adherence and its consequences. While treatment for chronic disease can be cumbersome, time-intensive, and bring about more side-effects, there’s a lot more at stake when, for example, a cancer patient misses their critical dose. While adherence technology (e.g. reminders built into pill boxes and medication sensors) will likely be an important component in the future, nothing replaces personal interactions with patients. Here are three tips for patient interaction to help improve medication adherence. 

Listen and Respond with Empathy

In the face of non-adherence, an obvious question to ask patients is ‘why’. And while that may seem like the first logical question to ask, it can also feel accusatory. 

A recent Pharmacy Times article gives some good advice on how to better spark the adherence topic. This is inline with the “motivational interviewing” method that focuses on decisional balance and internal motivation. For example, instead of starting the conversation with “Why aren’t you taking your medications?” you can rephrase the question as, “Many people have trouble taking their medications on a regular basis. Do you find that this is the case for any of your medications?”3 The phrasing of the second question removes the blame and shame by lending the perspective that many people struggle with taking their medications, it’s not just ‘you’.

When continuing the conversation, it’s easy to instantly get into advice-giving mode before gaining a little more understanding of the patient, especially when they are clearly not following their treatment plan. However, if the patient feels that you’re listening in a non-judgmental way and have some empathy first, they’re more likely to be honest, come to their own conclusions, and be more open to what you have to say. Examples of some questions to guide the conversation include: 

  • Sometimes we get busy and we do not take all the doses of our medicines.

    • How often do you have difficulty remembering to take all your medicines?

  • Taking medication every day is a real inconvenience for some people.

    • Do you ever feel hassled about sticking to your regimen?

    • What gets in the way of taking your medication as prescribed?(3)

Provide Multiple Means of Education for the Patient

To the prescriber and pharmacist, the correlation between following one’s treatment plan and positive outcomes is a given. To the patient who may not be seeing positive results right away (and on the flip side is seeing only the negative—i.e. side effects, high drug costs, and time intensive routines), it may not be so obvious. Especially with specialty drugs, educating the patient beyond just asking “are there any questions with your medication?” encourages adherence. Some ways to do this include:

  • Offer both in-person and online training for self-infusible and injectable medications

  • Provide programs that discuss the importance of therapy adherence and positive self-management

  • Encourage community outreach and support through events and online platforms

Check In Frequently

Similar to New Years Resolutions, we all have intentions of sticking to our plans. But without consistent and frequent accountability, intentions and will-power run dry. An online article published in U.S. Pharmacist, presents multiple studies where increased in-person pharmacist interaction led to increased adherence rates.4 While in-person interactions are typically the most effective, it’s unrealistic that all patients requiring specialty pharmacy drugs are within reasonable range of their physical specialty pharmacy location and/or are even able to get there on a regular basis. The good news is that text messaging has also shown to be effective. The same article cites a study where text messaging doubled the odds of medication adherence and improved overall adherence rates by 17.8%. There are several platform options available for sending automated texts at desired frequencies, encouraging a response and further dialogue. 

Medication adherence takes a joint effort in open communication between the patient, prescriber, and pharmacist. Allowing patients to feel heard in a non-judgmental environment, providing patient education, and frequently checking in with the patient all contribute to the patient taking more responsibility for their health. This leads to higher adherence rates, ultimately improving therapeutic outcomes.

BioMatrix Specialty Pharmacy is committed to provide an individualized clinical approach to specialty pharmacy and infusion services that improve health outcomes and empower patients to live each day to its fullest potential. Learn more. https://www.biomatrixsprx.com/about-us

Stay informed on the latest trends in healthcare and specialty pharmacy.

Sign up for our monthly e-newsletter, BioMatrix Abstract.

We value your privacy. Review our Privacy Policy here.

1. KFF website. https://www.kff.org/health-costs/state-indicator/total-retail-rx-drugs/

2. World Health Organization. Adherence to long term therapies: evidence for action. Geneva: WHO; 2003.

3. Marden B, Martineau C. Emphasize Medication Adherence to Patients. Pharmacy Times website. https://www.pharmacytimes.com/publications/health-system-edition/2019/September2019/emphasize-medication-adherence-to-patients

4. Medication Adherence: The Elephant in the Room. U.S. Pharmacist website. https://www.uspharmacist.com/article/medication-adherence-the-elephant-in-the-room

Read More

BioMatrix Specialty Pharmacy Celebrates GivingTuesday

BIOMATRIX SPECIALTY PHARMACY CELEBRATES GIVINGTUESDAY

Employees Support Programs Assisting Those in Need

Media Contact: Tara Marchese
Corporate Director of Marketing
Tel: 954-908-7636
Email: tara.marchese@biomatrixsprx.com

FOR IMMEDIATE RELEASE
[DOWNLOAD PDF]

giving20tuesday20slider.jpg

Weston, FL – December 3, 2019 – BioMatrix Specialty Pharmacy announced this GivingTuesday their participation in several initiatives supporting families in need across the country. During the month of November, BioMatrix partnered with the largest national hunger-relief organization, Feeding America. Feeding America has provided over 4 billion meals to individuals and families, working with an extensive nationwide network to end domestic hunger. BioMatrix also worked with Pajama Program to collect clothing and books for children. Pajama Program has delivered 4.2 million pairs of pajamas and distributed over 2 million books across the country.

GivingTuesday also marks the beginning of two additional BioMatrix initiatives – “Sleeves Up” and “Angel Trees.” Sleeves Up is an employee-based blood donation drive completed in partnership with the American Red Cross. Blood donation vehicles will be on site at several pharmacy locations as field employees pledge donations at local facilities. In addition to the blood drive, pharmacy and office staff at locations across the country today decorated “Angel Trees.” Angel Trees is a Salvation Army program providing a brighter holiday season to those in need. Each Angel Tree is adorned with tags that include a “wish” from a local family or individual in need. Employees choose wishes to grant from the tree, spreading cheer and lifting spirits for those facing adversity this holiday season.

“As a specialty pharmacy working every day to help patients experience better health, we are dedicated to service,” BioMatrix Culture Specialist Marquita Whittingham explains. “Lifting people up is a deep part of who we are.” The organization’s GivingTuesday initiatives engaged over 400 employees across 13 pharmacy locations and field representatives to celebrate generosity and give back to their communities.

About BioMatrix Specialty Pharmacy

BioMatrix Specialty Pharmacy offers comprehensive, nationwide specialty pharmacy services and digital health technology solutions for patients with chronic, difficult to treat conditions. Our commitment to every patient is to provide individualized pharmacy services, timely access to care, and focused education and support. We offer a tailored approach for a wide range of therapeutic categories, improving health and empowering patients to experience a higher quality of life.

About GivingTuesday

GivingTuesday is a global generosity movement unleashing the power of people and organizations to transform their communities and the world. GivingTuesday was created in 2012 as a simple idea: a day that encourages people to do good. Over the past seven years, it has grown into a global movement that inspires hundreds of millions of people to give, collaborate, and celebrate generosity.

Whether it’s making someone smile, helping a neighbor or stranger out, showing up for an issue or people we care about, or giving some of what we have to those who need our help, every act of generosity counts and everyone has something to give. GivingTuesday strives to build a world in which the catalytic power of generosity is at the heart of the society we build together, unlocking dignity, opportunity and equity around the globe.

To learn more about GivingTuesday participants and activities or to join the celebration of giving, please visit:

Website: www.givingtuesday.org

Read More

Video: Tips For Navigating Open Enrollment

BMX-OE-MC-HEADER.png

Are you ready for open enrollment?

Open enrollment occurs once annually and is the period of time when consumers can make changes to their health insurance benefits.

Join BioMatrix by watching the following video and you’ll learn tips and key information as it relates to:

  • Open Enrollment Dates

  • Insurance Terms

  • Key Questions to Ask

  • ACA Plans

  • Medicare

  • Plans + Policies

  • Financial Assistance Programs

The information contained in this video is provided for informational and educational purposes only, and should not be construed as legal or clinical advice on any subject matter.

Please direct any questions related to this webinar by email to: openenrollment@biomatrixsprx.com

Thank you!

About Shelby Smoak
Advocate & Education Specialist at BioMatrix Specialty Pharmacy

8f1473e8-c63c-4af6-98da-8521ab41e8e6.jpg

Shelby Smoak is a tireless advocate for patients with chronic health conditions. In the 90s, his experience living with a bleeding disorder and HIV led him to become actively involved in advocacy. He’s been saturated in the ever-changing dynamics of healthcare ever since. Shelby helps others understand complicated health policy and serves as a voice for patients with rare conditions across the nation. He’s been featured on TV and radio, including NPR. Shelby served on the board for the Hemophilia Association of the Capitol Area and currently serves on the Pfizer B2B board. A former literature professor, Shelby is also a writer and a musician. Awarded a Pen/American grant for writers living with HIV, Smoak holds a Ph.D. in Literature and an M.A. in English. His book, “Bleeder: A Memoir” received praise from sources as diverse as The Minneapolis Star Tribune, Library Journal, and Glamour, and has won several awards, including “Best of the Best” by the American Library Association.

Read More

BioMatrix Announces 2019 Academic Scholarship Recipients

BIOMATRIX ANNOUNCES 2019 ACADEMIC SCHOLARSHIP RECIPIENTS

Program Honors Memory of Bleeding Disorder Community Members

Media Contact: Tara Marchese
Corporate Director of Marketing
Tel: 954-908-7636
Email: tara.marchese@biomatrixsprx.com

FOR IMMEDIATE RELEASE
[DOWNLOAD PDF]

Weston, FL – November 19, 2019 – – BioMatrix Specialty Pharmacy announced today the recipients of their 2019 Memorial Scholarship Program. Six $1,500 academic scholarships honor the memory of several individuals who impacted the bleeding disorders community in unique ways. The 2019 reward recipients are pursuing a range of academic interests from nursing to neuroscience. BioMatrix partners with the Hemophilia Federation of America for administrative support and independent, third-party evaluation of applicants.

“BioMatrix is proud to offer these academic scholarships,” shares Tara Marchese, Corporate Director of Marketing at BioMatrix. “We are committed to helping members of the bleeding disorders community pursue and achieve their goals. Since 2013, our program has awarded $50,000 to 44 students across the country. Congratulations to all of the winners!”

BioMatrix Memorial Scholarship Winners

LENA COOK
Mark Coats Memorial Scholarship Recipient
Junior, California State Polytechnic University
Major: Kinesiology

Growing up as a female with hemophilia, Lena Cook encountered many challenges related to her diagnosis. “I’ve had to fight continuously for treatment and to keep my diagnosis,” she shares. Lena learned to advocate for herself and is determined to help others. Volunteering within the bleeding disorders community has ultimately led her to pursue a career in healthcare, where she is determined to help other “live the healthiest lives they possibly can.”

Congratulations, Lena!

Cook, Lena.jpeg

KENADIE HAMBLIN
Millie Gonzalez Memorial Scholarship Recipient
Junior, Utah Valley University
Major: Nursing

Von Willebrand Disease has been a positive influence in the life of Kenadie Hamblin. While it presented challenges growing up, her parents guided her to speak up and advocate for herself. The bleeding disorders community is where she ultimately met her husband and two best friends. “This community has been a place where I have always felt supported and encouraged to grow,” she shares. Today, Kenadie has her sights on becoming a pediatric hematology nurse.

Congratulations, Kenadie!

Hamblin, Kenadie.jpg

DANIEL LIEDL
Ron Niederman Memorial Scholarship Recipient
Doctoral Degree, West Virginia University
Sociology

By obtaining a Ph.D. in Sociology, Daniel Liedl plans to teach at a university and use sociological research to identify the needs of rare genetic disorders in rural communities. Understanding that rural healthcare facilities are not often knowledgeable in bleeding disorders and that government agencies utilize sociological research to identify needs, Daniel states, “By researching rural communities and learning what is missing and/or required to address these issues, future generations can avoid the hardships of the past.”

Congratulations, Daniel!

Liedl, Daniel.jpg

ISAIAH REEVES
Tim Kennedy Memorial Scholarship Recipient
University of Iowa Carver College of Medicine
Major: Medicine

Greatly influenced by the dedicated medical personnel who treated his hemophilia throughout his childhood, Isaiah Reeves is inspired to pursue a doctoral degree to become a pediatric hematologist/oncologist. Isaiah shares, “As a doctor, I will use my personal experiences, abilities and knowledge to support and enrich the lives of children. I will seek to emulate physicians from my own life who have been so impactful in making me the person I am today.”

Congratulations, Isaiah!

Reeves, Isaiah scholarship.jpg

GRACE REZNIKOV
Mike Hylton Memorial Scholarship Recipient
Sophomore, Virginia Tech
Major: Neuroscience

A loving relationship with her stepmother was a vital component in Grace Reznikov’s life. When her stepmother had a son with hemophilia, Grace realized how inequitable life could be, “What resonates with me most is the undeniable strength of the human spirit.” Grace believes the experience made the family stronger, “Our more worldly outlooks can hopefully inspire those around us to do good and, more than anything, love unconditionally, because nothing is guaranteed.”

Congratulations, Grace!

Reznikov, Grace.jpg

LAVANG VU
Joe Holibaugh Memorial Scholarship Recipient
Freshman, University of Dallas
Major: Biology and pre-medical studies
Minor: Music

Guiding Lavang Vu away from sports, his parents encouraged music. Playing various instruments and singing was a way to relieve the stress of living with hemophilia; it grew into a passion resulting in achieving state-level success. “I used the challenges that hemophilia gave me as a way to make my music-making better.” After suffering a severe infection resulting in a 49-day hospitalization, Lavang’s life direction shifted and he now aspires to become a pediatric hematologist.

Congratulations, Lavang!

BMX-Rachel.jpg

The BioMatrix Scholarship Program is in its 8th year and will begin accepting applicants on March 1, 2020 for the 2020/2021 academic school year.

About BioMatrix Specialty Pharmacy

BioMatrix Specialty Pharmacy offers comprehensive, nationwide specialty pharmacy services and digital health technology solutions for patients with chronic, difficult to treat conditions. Our commitment to every patient is to provide individualized pharmacy services, timely access to care, and focused education and support. We offer a tailored approach for a wide range of therapeutic categories, improving health and empowering patients to experience a higher quality of life.

Read More

Nick Karalis Named As New Chief Executive Officer At BioMatrix

NICK KARALIS NAMED AS NEW CHIEF EXECUTIVE OFFICER AT BIOMATRIX

Media Contact: Tara Marchese
Corporate Director of Marketing
Tel: 954-908-7636
Email: tara.marchese@biomatrixsprx.com

FOR IMMEDIATE RELEASE
[DOWNLOAD PDF]

Weston, FL – August 27, 2019 – BioMatrix Specialty Pharmacy announced today its Board of Directors unanimously selected Nick Karalis as the company’s Chief Executive Officer. Mr. Karalis, who currently serves as BioMatrix Chief Operating Officer, assumed the role on July 1, 2019. He will also serve on the company’s Board of Directors.

“We are pleased to select Nick as the CEO of BioMatrix,” shares Daniel Jinich, Chairman of the Board for BioMatrix. “Nick’s clinical experience as a pharmacist combined with his business acumen and deep understanding of the specialty pharmacy industry will serve the organization well.”

“I’m honored and grateful to the Board for the opportunity to lead this exceptional organization with dedicated professionals,” said Nick. “I’ve spent my entire career building and managing organizations uniting healthcare stakeholders to remove barriers to care and improve patient outcomes. We have an incredible team at BioMatrix and we are well positioned to become the premier national specialty pharmacy for patients with complex health conditions.”

Mr. Karalis is a graduate of University of the Sciences (formerly PCPS) and has over 25 years of executive leadership experience as a pharmacist and pharmacy owner/operator. He was a founding principal and CEO of Elwyn Pharmacy Group, which became part of BioMatrix in 2017. He also was a co-founder and President at Community Specialty Pharmacy Network (CSPN). Nick’s prior experience includes various pharmacy companies he founded and operated. He is a member of Cardinal Health’s National Advisory Board and on the Leadership Counsel for the American Red Cross. He is a founding Board member of Hellenic Hearts, a non-profit, and part of Leadership 100. Nick is an editorial board member of Specialty Pharmacy Times and the winner of the 2014 Smart/CEO Circle of Excellence award.

BioMatrix is a nationwide specialty pharmacy provider with 13 multi-accredited locations licensed in all 50 States. The family of companies include Matrix Health, Factor Support Network, MedEx BioCare, BiologicTx, Elwyn Pharmacy Group, Glen Rock Medical Pharmacy and Decillion Healthcare.

About BioMatrix Specialty Pharmacy

BioMatrix Specialty Pharmacy offers comprehensive, nationwide specialty pharmacy services and digital health technology solutions for patients with chronic, difficult to treat conditions. Our commitment to every patient is to provide individualized pharmacy services, timely access to care, and focused education and support. We offer a tailored approach for a wide range of therapeutic categories, improving health and empowering patients to experience a higher quality of life.

Read More

BioMatrix Specialty Pharmacy Earns Fifth Perfect URAC Score

BIOMATRIX SPECIALTY PHARMACY EARNS FIFTH PERFECT URAC SCORE

Assessment Earns Weston Pharmacy Location Accreditation in Specialty Pharmacy Services

Media Contact: Tara Marchese
Corporate Director of Marketing
Tel: 954-908-7636
Email: tara.marchese@biomatrixsprx.com

FOR IMMEDIATE RELEASE
[DOWNLOAD PDF]

Weston, FL – April 2, 2019 – BioMatrix Specialty Pharmacy proudly announced today that its Weston, Florida pharmacy location received a perfect score and earned URAC accreditation in specialty pharmacy services. URAC is a leading independent, non-profit accreditation entity promoting healthcare quality through leadership, accreditation, measurement and innovation. URAC accreditation demonstrates an organization’s ongoing commitment to quality, compliance, and continuous process improvement. This accreditation marks the fifth recent perfect URAC assessment for a BioMatrix pharmacy location.

"Accreditation validates our ability to deliver quality care and positive outcomes for all healthcare stakeholders,” Compliance Officer Robert Carter shared. “Our professionals provide exceptional pharmacy and support services that patients, payers, and providers across the country can rely on. We are very proud of the team for earning yet another perfect score.”

“It’s necessary for specialty pharmacies to provide a higher level of treatment for patients so desired outcomes are achieved. BioMatrix shows a dedication to patient education and safety through the recognition of quality it received with URAC’s independent accreditation,” said URAC President and CEO Kylanne Green. “With URAC accreditation, people know that BioMatrix strives to adhere to industry best practices.”

About BioMatrix Specialty Pharmacy

BioMatrix specialty pharmacy offers comprehensive, nationwide specialty pharmacy services and digital health technology solutions for patients with chronic, difficult to treat conditions. Our growing family of companies unites leaders in the specialty pharmacy industry to improve health and empower patients to experience a higher quality of life.

Read More

BioMatrix and Highmark Announce Settlement

BIOMATRIX AND HIGHMARK ANNOUNCE SETTLEMENT

Contact

For BioMatrix:
Tara Marchese
Corporate Director of Marketing
954-908-7636

For Highmark:
Aaron Bilger
VP Media / Communications
412-544-7826

FOR IMMEDIATE RELEASE
[DOWNLOAD PDF]

Weston, FL. and Pittsburgh, PA. – February 12, 2019 – BioMatrix Specialty Pharmacy and Highmark, Inc. jointly announced today that they have settled litigation pending between the two companies. 

This agreement enables both companies to focus on their respective commitments to providing high quality care for patients with chronic medical conditions. To ensure continuity of care, BioMatrix and Highmark will continue to service patients who live in Pennsylvania, Delaware, and West Virginia.

“We are pleased to have reached this mutual settlement and commend Highmark for its enduring commitment to care for people with hemophilia and other chronic conditions,” Nicholas Karalis, BioMatrix’s interim COO and founder of Elwyn Pharmacy Group, said. “We look forward to working with Highmark to build a partnership that will drive the best possible outcomes for our mutual patients.”

Aaron Bilger, VP Internal & External Communications at Highmark Health said: “We are thankful that, as a result of this agreement, specialty medications BioMatrix provides will be widely available across our network.”

About BioMatrix Specialty Pharmacy

BioMatrix Specialty Pharmacy offers comprehensive, nationwide specialty pharmacy services and digital health technology solutions for patients with chronic, difficult to treat conditions. Our growing family of companies unites leaders in the specialty pharmacy industry to improve health and empower patients to experience a higher quality of life. The current BioMatrix family of companies includes:, BiologicTx, Decillion Healthcare, Elwyn Pharmacy Group, Factor Support Network, Matrix Health, and Medex BioCare.

About Highmark Inc.

Highmark Inc. and its health insurance subsidiaries and affiliates collectively are one of America’s largest health insurance organizations and together with its Blue-branded affiliates, collectively comprise the third-largest overall Blue Cross and Blue Shield-affiliated organization in the country based on capital. Highmark Inc. and its affiliates operate health insurance plans in Pennsylvania, Delaware and West Virginia that serve approximately 4.6 million members and hundreds of thousands of additional individuals through the BlueCard® program. Its diversified businesses serve group customer and individual needs across the United States through dental insurance, vision care and other related businesses. Highmark Inc. is an independent licensee of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield companies. For more information, visit www.highmark.com.

Read More

BioMatrix Specialty Pharmacy Partners with The National Hemophilia Foundation and Audaire Health to Improve Care for Patients with Bleeding Disorders

BIOMATRIX SPECIALTY PHARMACY PARTNERS WITH THE NATIONAL HEMOPHILIA FOUNDATION AND AUDAIRE HEALTH TO IMPROVE CARE FOR PATIENTS WITH BLEEDING DISORDERS

Innovative Digital Platform Increases Transparency and Accountability for Patients and Providers

Media Contact: Tara Marchese
Corporate Director of Marketing
Tel: 954-908-7636
Email: tara.marchese@biomatrixsprx.com

FOR IMMEDIATE RELEASE
[DOWNLOAD PDF]

Weston, FL – December 3, 2018 – BioMatrix Specialty Pharmacy announced today participation in a pilot program with the National Hemophilia Foundation (NHF) and Audaire Health Inc (Audaire) focused on reducing administrative burden, increasing patient adherence, and lowering health care costs. Pilot participants include a small group of select pharmacies and Hemophilia Treatment Centers (HTCs) who will utilize Audaire’s innovative data tracking tool demonstrating how the system can reduce cost of care and improve outcomes.

Andrew Berg, CEO at Audaire asserts, “We are thrilled to announce our partnership with NHF and BioMatrix. It’s a pleasure to find two partners as dedicated to simplifying the patient experience as we are. Our goal was to find pharmacy partners who value transparency, accountability, and driving better patient outcomes. BioMatrix is most definitely that partner.”

The Audaire Platform allows patients to instantly record infusions by utilizing their smartphone (at home or on the go) or a small electronic device kept in the home. The HIPAA-compliant system offers treatment reminders and passive logging capabilities that instantly transmit infusions to the patient’s care team. This “real-time” reporting provides opportunities for early intervention, preventing unnecessary and costly emergency room visits and/or hospitalizations. The Audaire Platform is unique in comparison to other logging devices. The system provides a nearly passive data input solution designed to ease reporting burden for patients and pharmacy providers. By capturing multiple data points including prescription, dispensation, pharmacy/clinic touch points, reported bleeds and other medication administration information, the Audaire Platform provides more robust capabilities than current logging systems.

“NHF believes that following prescribed treatments is a key to lowering costs and improving quality of life for people with bleeding disorders,” said Val D. Bias, CEO of the National Hemophilia Foundation. “We hope this program can make a real difference in people’s lives.”

“BioMatrix has a history of leveraging unique digital health technology producing positive outcomes for patients and reducing healthcare costs,” BioMatrix Chief Clinical Officer Marc Stranz shares. “This program demonstrates our commitment to providing the tools and support that make managing a chronic condition easier.”

Data from the pilot will be evaluated to identify the number of meaningful interventions resulting in cost reductions and or avoidance, changes in patient adherence and reporting rates, and improvements in assay and inventory management processes. The program is limited to patients on service with providers participating in the pilot. Initial findings will be shared at relevant industry symposia in 2019.

About BioMatrix Specialty Pharmacy

BioMatrix specialty pharmacy offers comprehensive, nationwide specialty pharmacy services and digital health technology solutions for patients with chronic, difficult to treat conditions. Our growing family of companies unites leaders in the specialty pharmacy industry to improve health and empower patients to experience a higher quality of life. The current BioMatrix family of companies includes:, BiologicTx, Decillion Healthcare, Elwyn Pharmacy Group, Factor Support Network, Matrix Health, and Medex BioCare.

About the National Hemophilia Foundation

Established in 1948, National Hemophilia Foundation (NHF) is a national nonprofit patient advocacy organization dedicated to finding better treatments and cures for inheritable bleeding disorders and to preventing the complications of these disorders through education, advocacy and research. NHF is a leader in supporting innovative solutions to help people with bleeding disorders and their families manage their disorder and improve their quality of life.

About Audaire Health

Audaire Health Inc (Audaire) is a healthcare technology company that focuses on facilitating transparency and accountability between payer, provider, pharmacy and patient. On the front end, Audaire's patent pending platform allows patients to seamlessly log medication adherence and exacerbations in real time. On the back end, all stakeholders (payers, providers, pharmacies) have real time insight into patient behavior, physician behavior and pharmacy dispensations. The end result is more informed providers, better performing pharmacies, and better patient outcomes.

Read More

BioMatrix Announces 2018 Academic Scholarship Recipients

BIOMATRIX ANNOUNCES 2018 ACADEMIC SCHOLARSHIP RECIPIENTS

Program Honors Memory of Bleeding Disorder Community Members

Media Contact: Tara Marchese
Corporate Director of Marketing
Tel: 954-908-7636
Email: tara.marchese@biomatrixsprx.com

FOR IMMEDIATE RELEASE
[DOWNLOAD PDF]

Weston, FL – November 27, 2018 – In honor of Giving Tuesday, BioMatrix Specialty Pharmacy announced today the recipients of their 2018 Memorial Scholarship Program. Six $1,500 academic scholarships were awarded to deserving applicants. The program honors the memory of several individuals who impacted the bleeding disorder community in unique ways. BioMatrix partners with the Hemophilia Federation of America for administrative support and independent, third-party evaluation of applicants.

“BioMatrix firmly believes in empowering patients to become strong self-advocates and leaders in their communities,” Tara Marchese, Corporate Director of Marketing at BioMatrix shares. “Our scholarship program honors the legacy of those memorialized by lifting up the next generation of leaders.”

The 2018 reward recipients are pursuing a range of academic interests from medicine to religion.

BioMatrix Memorial Scholarship Winners

MILES COLE
Joe Holibaugh Memorial Scholarship Recipient
Sophomore, Princeton University
Major: Undeclared

Taking his bleeding disorder in stride, Miles never lets severe hemophilia stop him from achieving his dreams. Very athletic throughout his life, he competed internationally with the USA Junior National Water Polo Team. “I grew up believing that as long as I was diligent about my meds, hemophilia did not have to define or limit my activities.” Miles adamantly offers, “Take charge of your life to shape it how you want it to be.”

BMX-Miles.jpg

LENA COOK
Millie Gonzalez Memorial Scholarship Recipient
Sophomore, California State Polytechnic University
Major: Kinesiology

Growing up as a female with hemophilia, Lena encountered challenges related to her diagnosis. “I have been told it is not possible for me to have hemophilia,” she shares. Lena learned to advocate for herself and is determined to help others. She started a women’s support group at her local chapter, “It was a fantastic opportunity to share our stories. It reaffirmed my

commitment to finding effective treatments for myself and other women with bleeding disorders.”

BMX-Lena.jpg

CALEB CROTHER
Mike Hylton Memorial Scholarship Recipient
Freshman, Westmont College
Major: Religious Studies

Salutatorian of his high school, Caleb enters college with the same gusto for learning and achieving. In addition to academics, Caleb plays five musical instruments and is very involved in his local community. He has received numerous accolades for his academic accomplishments and volunteer efforts. He affirms, “Having a bleeding disorder has helped me realize that as much as your community helps you, you should go and help your community.”

JUSTIN NAJIMIAN
Tim Kennedy Memorial Scholarship Recipient
Freshman, Rutgers University
Major: Public Health

“I carry my hemophilia gene not as a burden, but as a torch that gives light to the memories of generations past and blazes the trail for a new generation of leaders.” Like his beloved grandfather, Justin has hemophilia. He plans to pursue a career in public

health. “Healthcare policy, social work, advocacy or non-profit work are all paths I can see myself taking. Through advocacy and outreach, I would aim to bring camaraderie and care to hemophiliacs across the board.”

BMX-Justin.jpg

ISAIAH REEVES
Mark Coats Memorial Scholarship Recipient
University of Iowa
Carver College of Medicine, Major: Medicine

Isaiah was greatly influenced by his childhood physicians who treated his hemophilia. Inspired by those who helped him, he is pursuing a doctoral degree to become a pediatric hematologist/oncologist. “As a doctor, I will use my personal experiences, abilities and knowledge to support and enrich the lives of children. I will seek to emulate physicians from my own life who have been so impactful in making me the person I am today.”

BMX-Isaiah.jpg

RACHEL WILE
Ron Niederman Memorial Scholarship Recipient
Junior, UCLA
Major: Integrative Biology and Physiology

Rachel grew up hearing stories of the challenges her family members faced living with severe hemophilia. The experiences of her father and her uncle inspired Rachel to pursue a career in medicine. She hopes to conduct research leading to advancements in care for people with hemophilia. She shares, “Through my ongoing education and training, I hope one day to have a positive impact on the lives of those with bleeding disorders in this country and throughout the world.”

BMX-Rachel.jpg

About BioMatrix Specialty Pharmacy

BioMatrix specialty pharmacy offers comprehensive, nationwide specialty pharmacy services and digital health technology solutions for patients with chronic, difficult to treat conditions. Our growing family of companies unites leaders in the specialty pharmacy industry to improve health and empower patients to experience a higher quality of life. The current BioMatrix family of companies includes:, BiologicTx, Decillion Healthcare, Elwyn Pharmacy Group, Factor Support Network, Matrix Health, and Medex BioCare.

Read More

Medex Biocare Earns Perfect Score In URAC Specialty Pharmacy Accreditation

MEDEX BIOCARE EARNS PERFECT SCORE IN URAC SPECIALTY PHARMACY ACCREDITATION

Fourth Member Of The BioMatrix Family Of Companies To Receive Perfect URAC Score

Media Contact: Tara Marchese
Corporate Director of Marketing
Tel: 954-908-7636
Email: tara.marchese@biomatrixsprx.com

FOR IMMEDIATE RELEASE
[DOWNLOAD PDF]

Weston, FL – October 2, 2018 – Medex BioCare, a member of the BioMatrix family of companies, proudly announced today that it has received a perfect score and earned URAC accreditation in specialty pharmacy services for its Bartlett, Tennessee facility. This accreditation marks the fourth perfect URAC assessment score for a BioMatrix company, and the second within the last 16 months. URAC is the independent leader in promoting healthcare quality through leadership, accreditation, measurement and innovation. By achieving this status, Medex BioCare has demonstrated a comprehensive commitment to quality care, improved processes, and better patient outcomes.

"Patient care is our top priority. Receiving a perfect score and obtaining URAC accreditation validates our commitment to exceptional patient care and the effort we put forth to ensure consistency and compliance throughout our organization", stated Nicholas Karalis, Chief Operating Officer at BioMatrix Specialty Pharmacy. "I am thrilled with the efforts of the team at Medex BioCare and look forward to expanding URAC accreditation to all BioMatrix pharmacies."

“It’s necessary for specialty pharmacies to provide a higher level of treatment for patients so desired outcomes are achieved. Medex BioCare shows a dedication to patient education and safety through the recognition of quality it received with URAC’s independent accreditation,” said URAC President and CEO Kylanne Green. “With URAC accreditation, people know that Medex BioCare strives to adhere to industry best practices.”

About Medex BioCare

Medex BioCare, a member of the BioMatrix family of companies, is a specialty pharmacy dedicated to providing therapies and support for people with chronic conditions such as

bleeding disorders, neurological and immunological disorders, solid organ transplants, hepatitis C, HIV, and more. We are committed to providing individualized, patient-focused services to promote better health through encouraging positive self-management and building a local network of support.

About BioMatrix Specialty Pharmacy

BioMatrix specialty pharmacy offers comprehensive, nationwide specialty pharmacy services and digital health technology solutions for patients with chronic, difficult to treat conditions. Our growing family of companies unites leaders in the specialty pharmacy industry to improve health and empower patients to experience a higher quality of life. The current BioMatrix family of companies includes:, BiologicTx, Decillion Healthcare, Elwyn Pharmacy Group, Factor Support Network, Matrix Health, and Medex BioCare.

Read More

BioMatrix Announces Sponsorship For “Blood Work” 2018

BIOMATRIX ANNOUNCES SPONSORSHIP FOR “BLOOD WORK” 2018

Project Features Artwork from the Bleeding Disorders Community

Media Contact: Tara Marchese
Corporate Director of Marketing
Tel: 954-908-7636
Email: tara.marchese@biomatrixsprx.com

FOR IMMEDIATE RELEASE
[DOWNLOAD PDF]

Weston, FL – September 13, 2018 – BioMatrix specialty pharmacy announced today their support for “Blood Work 2018.” Blood Work celebrates creative expression within the bleeding disorders community. Submissions from across the country will be displayed in an interactive gallery for thousands of attendees at the National Hemophilia Foundation’s annual bleeding disorder conference this October in Orlando, Florida. Celebrating the many shapes and forms of creativity, featured works include paintings, music, fashion, and more. In its fifth installment, Blood Work is organized by the National Hemophilia Foundation and FOLX – a nonprofit organization working to promote the inclusion, visibility, and empowerment of people with diverse backgrounds in the bleeding disorders community.

BioMatrix is a founding sponsor of the Blood Work program and is proud to continue another year of support. Corporate Director of Marketing Tara Marchese shares, “We’re pleased to partner again with the National Hemophilia Foundation and FOLX on the fifth installment of Blood Work. Every year we are amazed at the incredible creativity and talent on display. It is a powerful representation of what it’s like to live with a bleeding disorder through the patient’s eyes.” Review submission criteria and other instructions here.

About BioMatrix Specialty Pharmacy

BioMatrix specialty pharmacy offers comprehensive, nationwide specialty pharmacy services and digital health technology solutions for patients with chronic, difficult to treat conditions. Our growing family of companies unites leaders in the specialty pharmacy industry to improve health and empower patients to experience a higher quality of life. The current BioMatrix family of companies includes:, BiologicTx, Decillion Healthcare, Elwyn Pharmacy Group, Factor Support Network, Matrix Health, and Medex BioCare.

Read More